Pretreatment characteristics of 15 patients with relapsed or refractory HCL
Patient no. .  | Age, y/sex .  | Prior therapy .  | Time from diagnosis, mo .  | Granulocytes, × 109/L .  | Hgb, g/dL .  | Platelets, × 109/L .  | Absolute CD4 count .  | β2-microglobulin, mg/dL .  | 
|---|---|---|---|---|---|---|---|---|
| 1 | 60/M | IFN-α, 2-CdA × 2 | 103 | 3.6 | 13.4 | 196 | 484 | 2.6 | 
| 2 | 47/M | Splenectomy, DCF | 72 | 1.1 | 7.2 | 311 | 343 | 1.4 | 
| 3 | 66/F | 2-CdA | 111 | 1.5 | 11.7 | 92 | 474 | 2.3 | 
| 4 | 49/M | 2-CdA | 80 | 2.9 | 15.9 | 167 | 481 | 1.3 | 
| 5 | 44/M | 2-CdA | 39 | 2.2 | 13.4 | 231 | 595 | 1.7 | 
| 6 | 41/F | 2-CdA | 72 | 1.2 | 13.0 | 75 | 569 | 1.5 | 
| 7 | 35/M | 2-CdA | 4 | 0.1 | 9.2 | 59 | — | 1.4 | 
| 8 | 60/M | 2-CdA × 2, splenectomy, IFN-α | 72 | 0.6 | 10.0 | 104 | — | 3.3 | 
| 9 | 52/M | DCF, IFN-α, fludarabine, 2-CdA × 3 | 84 | 1.1* | 12.2 | 103 | 119 | 1.5 | 
| 10 | 58/M | IFN-α, 2-CdA, IFN-α, 2-CdA | 126 | 1.2 | 11.2 | 88 | — | — | 
| 11 | 59/M | 2-CdA | 107 | 1.3 | 11.4 | 99 | 306 | 1.5 | 
| 12 | 71/F | 2-CdA × 2 | 46 | 2.3* | 10.6 | 90 | 260 | 3.7 | 
| 13 | 28/M | 2-CdA | 6 | 1.5* | 14.8 | 79 | 1430 | 1.7 | 
| 14 | 63/M | 2-CdA | 106 | 0.1 | 7.2 | 29 | 225 | 3.9 | 
|  15  |  65/M  |  Splenectomy, IFN-α, DCF, 2-CdA  |  225  |  0.9  |  13.4  |  121  |  —  |  1.8  | 
Patient no. .  | Age, y/sex .  | Prior therapy .  | Time from diagnosis, mo .  | Granulocytes, × 109/L .  | Hgb, g/dL .  | Platelets, × 109/L .  | Absolute CD4 count .  | β2-microglobulin, mg/dL .  | 
|---|---|---|---|---|---|---|---|---|
| 1 | 60/M | IFN-α, 2-CdA × 2 | 103 | 3.6 | 13.4 | 196 | 484 | 2.6 | 
| 2 | 47/M | Splenectomy, DCF | 72 | 1.1 | 7.2 | 311 | 343 | 1.4 | 
| 3 | 66/F | 2-CdA | 111 | 1.5 | 11.7 | 92 | 474 | 2.3 | 
| 4 | 49/M | 2-CdA | 80 | 2.9 | 15.9 | 167 | 481 | 1.3 | 
| 5 | 44/M | 2-CdA | 39 | 2.2 | 13.4 | 231 | 595 | 1.7 | 
| 6 | 41/F | 2-CdA | 72 | 1.2 | 13.0 | 75 | 569 | 1.5 | 
| 7 | 35/M | 2-CdA | 4 | 0.1 | 9.2 | 59 | — | 1.4 | 
| 8 | 60/M | 2-CdA × 2, splenectomy, IFN-α | 72 | 0.6 | 10.0 | 104 | — | 3.3 | 
| 9 | 52/M | DCF, IFN-α, fludarabine, 2-CdA × 3 | 84 | 1.1* | 12.2 | 103 | 119 | 1.5 | 
| 10 | 58/M | IFN-α, 2-CdA, IFN-α, 2-CdA | 126 | 1.2 | 11.2 | 88 | — | — | 
| 11 | 59/M | 2-CdA | 107 | 1.3 | 11.4 | 99 | 306 | 1.5 | 
| 12 | 71/F | 2-CdA × 2 | 46 | 2.3* | 10.6 | 90 | 260 | 3.7 | 
| 13 | 28/M | 2-CdA | 6 | 1.5* | 14.8 | 79 | 1430 | 1.7 | 
| 14 | 63/M | 2-CdA | 106 | 0.1 | 7.2 | 29 | 225 | 3.9 | 
|  15  |  65/M  |  Splenectomy, IFN-α, DCF, 2-CdA  |  225  |  0.9  |  13.4  |  121  |  —  |  1.8  | 
Patient nos. 2 and 14 both transfusion-dependent of packed red blood cells, with the latter also platelet transfusion dependent. Patient nos. 6, 7, 8, and 12 had splenomegaly more than 5 cm below costal margin. 2-CdA × denotes number of salvage attempts with 2-CdA; and —, not done.
Circulating hairy cells